Product Description
ALTA3263, a KRAS isoform selective compound with improved drug-like properties and ON state inhibition to target >90% of KRAS mutations. (Sourced from: https://www.alterome.com/programs/)
Mechanisms of Action: KRAS G12D Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Alterome Therapeutics, Inc.
Company Location: Western America
Company Founding Year: 2021
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Adenocarcinoma|Colorectal Cancer|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06835569 |
NCT06835569 | P1 |
Recruiting |
Non-Small-Cell Lung Cancer|Pancreatic Ductal Carcinoma|Pancreatic Cancer|Adenocarcinoma|Colorectal Cancer |
2029-05-01 |
12% |
2026-06-11 |
Patient Enrollment|Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/02/2026 |
News Article |
Alterome Therapeutics Appoints Leo Faoro, MD, MBA, as Chief Medical Officer |
|
04/10/2025 |
News Article |
Alterome Therapeutics Announces New Chief Executive Officer and Chair of the Board of Directors |
|
03/10/2025 |
News Article |
Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors |
|
02/25/2025 |
News Article |
Alterome Therapeutics to Participate in Upcoming Investor Conferences |